Current RA treatments, while effective for some, often fall short of providing long-term remission owing to the disease’s complexity, leaving many patients cycling through therapies like methotrexate and biologics without sustained relief. Here, rosnilimab stands out as novel by targeting the PD-1 pathway, aiming to reset the immune system through the selective depletion of pathogenic…
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance
For millions living with rheumatoid arthritis (RA), the path to effective treatment is often a frustrating cycle of trial and error. Typically beginning with disease-modifying antirheumatic drugs (DMARDs) like methotrexate, the goal is low disease activity. Yet RA’s heterogeneity means many patients cycle through various therapies—biologic DMARDs like anti-TNF agents, JAK inhibitors, IL-6 receptor antagonists,…